STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-06-14
Here’s whether Amgen Inc (AMGN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 63 — healthy momentum range; strong 1-year return of +19.5%. Concerns: 50-day MA is falling (-0.46% over 10 days). Currently 9.2% off its 52-week high. Score: +4/7.
AMGN is in a confirmed uptrend, trading above both its 50-day ($340.31) and 200-day ($330.73) moving averages. An RSI of 62.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +19.5% compares to +22.9% for SPY (trailed the market by 3.4%).
$10,000 invested 1 year ago→ $11,948 today
vs. S&P 500 (SPY) — same period trailed market by 3.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($330.73)
✓Above 50-day MA ($340.31)
✓RSI(14) neutral zone (30–70) — currently 62.5
✓Positive return (+19.5%)
✓Within 10% of period high (−9.2%)
Period Range $355.20
$267.83$391.29
RSI (14) 62.5
0 · OversoldOverbought · 100
Key Metrics
Price$355.20
Period Return+19.5%
Period High$391.29
Period Low$267.83
Drawdown−9.2%
MA-50$340.31
MA-200$330.73
RSI (14)62.5
Avg Volume (30d)2.7M
vs. SPYtrailed by 3.4%
Return Rank#537 of 1246
Trend Signals
Price is above the 200-day moving average ($330.73)
Price is above the 50-day moving average ($340.31)